DXR: Daxor Corp Growth-Adjusted Market Cap to Net Income

Daxor Corporation leads in blood volume diagnostics thanks to its FDA-approved BVA-100 device. An impeccable reputation in cardiology confirms its status as the gold standard for measurements. This mature technology is critical for precise fluid management in intensive care. The PEG multiple on this chart helps assess the asset's undervaluation, while 0.00 determines the current value of the indicator.

The PEG ratio compares the market value of earnings to their expansion rate to determine an asset's fair value. A value below one indicates fundamental undervaluation relative to earnings growth. By analyzing the P/E-to-growth chart, an investor can see the scaling efficiency of the BVA-100 system and the steady income generated from consumables. This metric confirms the resilience of the B2B model of Daxor Corporation (DXR). This makes the company a promising target for long-term capital.